Navigation Links
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Date:6/12/2008

clinical trials at high and low doses of PTC124, TEPD assessments showed statistically significant improvements of mean CFTR-dependent chloride secretion in the airways.

The Phase 2a extension study in Israel assessed 3 months of oral PTC124 therapy at two different dose levels in 19 adult men and women with nonsense- mutation-mediated CF who had participated in a prior short-term PTC124 Phase 2a study. More than 90% of the patients had chronic CF-related lung infection and also had CF-induced pancreatic insufficiency. Results from the study showed that treatment with PTC124 resulted in statistically significant (p< 0.001) improvements in CFTR function as measured by TEPD in both dose groups. The proportion of patients showing improvement in TEPD chloride secretion increased over time in the extension study. Trends towards improvements in mean FEV1 and FVC values were observed. Baseline data showed that CF patients cough a remarkable 643 times per day on average, with a range of 324 to 1,569 coughs per day. In comparison, healthy individuals generally cough fewer than 16 times per day, according to the European Respiratory Journal (Hsu 1994). Patients receiving PTC124 experienced a mean [28%] decrease in cough frequency by the end of three months of therapy (p< 0.01). PTC124 was generally well tolerated, resulting in excellent mean compliance with the treatment regimen ( >90%).

"Three months of treatment with PTC124 in nonsense-mutation-mediated CF patients was associated with time-dependent improvements in nasal TEPD chloride conductance, pulmonary function and cough -- important markers suggesting the potential for benefit in patients with CF," stated Dr. Wilschanski. "PTC124 increases CFTR-mediated chloride secretion in patients with a variety of nonsense mutation types, which suggests a broad spectrum of activity across one of the major subpopulations in CF."

Dr. Kerem added, "The impact on cough that we observed in this study by objective
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 24, 2015 Research ... of the "Global Array Instruments Market 2015-2019" ... global array instruments market to grow at a ... The global array instruments market can be ... and others including tissue microarrays and cell microarrays. ...
(Date:6/30/2015)... 2015  Inari Medical, Inc. announced today that it ... financing. The financing was led by members of the ... US Venture Partners.  The round also included participation by ... very pleased to complete this financing with the support ... , who joined in February 2015 as President and ...
(Date:6/30/2015)... ALISO VIEJO, Calif. , June 30, 2015 ... from the PRISM II study showing that treatment ... statistically significant reduction in symptoms of pseudobulbar affect ... or stroke. PBA is a distressing condition characterized ... crying resulting from certain neurologic diseases or brain ...
Breaking Medicine Technology:Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:6/30/2015)... , ... June 30, 2015 , ... The American Lung ... at a media event in San Diego. Speakers and clean air advocates included San ... medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president of Sullivan ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, ... they have been awarded the exclusive billing agreements with Jackson Radiology Associates in ... services encompassing their proprietary suite of billing process software functionality called Experience Based ...
(Date:6/30/2015)... Beach, CA (PRWEB) , ... June 30, 2015 , ... ... Skilled Nursing”, which features multiple patient and family member testimonials. Medicare rated the care ... country. Broadway plans to use the video to give future patients a firsthand look ...
(Date:6/30/2015)... ... 2015 , ... Family and professional dementia caregivers are invited ... 9, 2015 at the Hyatt Regency Denver Tech Center from 7:30 am-4:30 pm. ... Campbell, the wife and daughter of singer Glen Campbell, who will discuss their ...
(Date:6/30/2015)... ... ... Rocky Mountain Oils, a leading non-MLM supplier of premium essential oils, ... Mr. Darold Francis. The changes will help enhance the company’s focus on strict product ... to know and respect for over eight years. , “I am thrilled to join ...
Breaking Medicine News(10 mins):Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2
... and Drug Administration approved naltrexone for the treatment of ... drug therapy available was disulfiram, or Antabuse, which provokes ... sobering doubts on earlier claims that an alcoholism drug ... is sponsoring a large trial comparing naltrexone, which is ...
... Americans living on their own takes a medication that ... According to the report, more than 21% of elderly ... of these 33 potentially inappropriate medications in 1996. ... always avoid, including certain sedatives, long-acting drugs to bring ...
... more likely than women to suffer eyelid droop as they age, ... side and front view photographs// of the eyes of 256 people ... that after the age of 35, the lower eyelid started to ... as women. Sagging is caused by the increased laxity of eyelid ...
... by burning away small amounts of heart tissue is as ... to new research.// The radiofrequency catheter ablation (RFCA) treatment involves ... - into the area of the heart which is struggling ... mild painless burst of radiofrequency energy, similar to microwave heat, ...
... the bed for sleep and sex rather than popping sedatives, ... pills worked in the// short-term, but only changing their behaviour ... defined as trouble falling asleep, waking frequently in the night ... to get back to sleep.Less than 15% get any treatment ...
... to impotence have prompted one in eight viewers to get ... about the drug and possible side effects. TV commercials for ... Administration set up rules and made them legal. // ... effect -- nearly a third of adults have talked to ...
Cached Medicine News:Health News:Cure for sleepless nights 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: